Compare Medpace Holdings Inc (MEDP) vs Nu Holdings Ltd (NU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Nu Holdings Ltd — how do they compare? Medpace Holdings Inc trades at $530 (market cap $15.08B), while Nu Holdings Ltd trades at $14.41 (market cap $67.58B). The key difference: Nu Holdings Ltd is far larger — about 4.5× Medpace Holdings Inc's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Nu Holdings Ltd nearer its low. Which is the better fit depends on your goals.
| MEDP | NU | |
|---|---|---|
Market Cap | $15.08B | $67.58B |
Sector | Technology | Financials |
52-Week High | $620.59 | $18.76 |
52-Week Low | $308.88 | $11.60 |
Enterprise Value | $14.55B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $527.93, down 1.82% on the day, with a neutral technical signal and mixed oscillators. The stock shows strong profitability with a 17.19% net margin and 77.25% ROE, though valuations are elevated with a P/E of 33.22. Recent quarters have consistently beaten EPS estimates, but a class action lawsuit filed in June 2026 adds uncertainty. Revenue is projected to grow to $2.7B in 2026, while cash flow trends improve from negative to positive net cash flow.
The outlook is cautious due to high valuation and legal overhangs, but fundamental strength in earnings and backlog quality provides support. Analyst consensus is mixed with a $497 price target below current levels, indicating limited near-term upside. Key risks include lawsuit outcomes and competitive pressures in the CRO sector.
NU stock trades at $14.39, up 5.89% in the last session, with a bullish technical signal from moving averages and strong fundamental growth. Revenue surged from $3.0B in 2022 to $10.63B in 2025, while net income turned positive to $2.87B. Recent news highlights expansion in Brazil and Mexico, including a new banking license, supporting continued growth momentum.
Outlook remains positive with a consensus price target of $14.98, though risks include rapid credit expansion and increased provisions. The stock offers exposure to Latin America's digital banking growth but faces execution risks in new markets and competitive pressures. Analyst sentiment is bullish with 55% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Nu Holdings Ltd
Nu Holdings Ltd is engaged in providing digital banking services. It offers several financial services such as Credit cards, Personal Account, Investments, Personal Loans, Insurance, Mobile payments, Business Account, and Rewards.
Read more on NU →
